JP2010523682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523682A5 JP2010523682A5 JP2010503086A JP2010503086A JP2010523682A5 JP 2010523682 A5 JP2010523682 A5 JP 2010523682A5 JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010523682 A5 JP2010523682 A5 JP 2010523682A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkoxy
- halogen
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 12
- 125000002757 morpholinyl group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- -1 amino, morpholinyl Chemical group 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000000466 oxiranyl group Chemical group 0.000 claims 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 3
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102000012936 Angiostatins Human genes 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000011057 Breast sarcoma Diseases 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229940087620 aromasin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims 1
- 229950010152 halofuginone Drugs 0.000 claims 1
- 229950000038 interferon alfa Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229960002633 ramucirumab Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229950001248 squalamine Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91161207P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/004809 WO2008127714A1 (en) | 2007-04-13 | 2008-04-12 | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523682A JP2010523682A (ja) | 2010-07-15 |
| JP2010523682A5 true JP2010523682A5 (enExample) | 2011-10-20 |
Family
ID=39618825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503086A Pending JP2010523682A (ja) | 2007-04-13 | 2008-04-12 | 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100158858A1 (enExample) |
| EP (1) | EP2139476A1 (enExample) |
| JP (1) | JP2010523682A (enExample) |
| AU (1) | AU2008239598A1 (enExample) |
| CA (1) | CA2683444A1 (enExample) |
| WO (1) | WO2008127714A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US8076353B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| EA201200555A1 (ru) * | 2004-03-15 | 2013-01-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Производные карболина, полезные в ингибировании ангиогенеза |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US9345739B2 (en) * | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| WO2010138695A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| MX2011012517A (es) | 2009-05-27 | 2012-01-27 | Ptc Therapeutics Inc | Procesos para la preparacion de tetrahidro beta - carbolina sustituidas. |
| HUE052510T2 (hu) | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| WO2010138685A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| US20120157402A1 (en) * | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| WO2010138706A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| PE20160874A1 (es) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| WO2015031759A1 (en) * | 2013-08-31 | 2015-03-05 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for re-activating epstein-barr virus and screening compounds therefor |
| BR112016030690B1 (pt) * | 2014-06-27 | 2023-11-14 | Nogra Pharma Limited | Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos |
| CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| JP2019001715A (ja) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
| US20190142811A1 (en) | 2016-04-01 | 2019-05-16 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | INFLAMMATION TREATMENT COMPOSITIONS AND METHODS |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| US10519152B2 (en) * | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| TWI915239B (zh) | 2018-06-21 | 2026-02-11 | 瑞士商赫孚孟拉羅股份公司 | 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法 |
| BR112021001859A2 (pt) | 2018-08-03 | 2021-04-27 | Ptc Therapeutics, Inc. | formas de dosagem oral biodisponíveis |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| AU2020209767B2 (en) | 2019-01-15 | 2025-03-06 | Ptc Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
| EP3993787A4 (en) | 2019-08-06 | 2023-07-12 | Recurium IP Holdings, LLC | Estrogen receptor modulators for treating mutants |
| CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US254878A (en) * | 1882-03-14 | Train-boat | ||
| US282849A (en) * | 1883-08-07 | Fruit-jar | ||
| US40527A (en) * | 1863-11-03 | Improvement in cooking-stoves | ||
| US64683A (en) * | 1867-05-14 | mason and joseph messinger | ||
| US272759A (en) * | 1883-02-20 | Desk-top | ||
| US20030158168A1 (en) * | 2000-08-09 | 2003-08-21 | Giorgio Massimini | Composition for combined use of aromatase inhibitors |
| ES2272695T3 (es) * | 2001-02-12 | 2007-05-01 | Lilly Icos Llc | Derivados de carbolina. |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
-
2008
- 2008-04-12 AU AU2008239598A patent/AU2008239598A1/en not_active Abandoned
- 2008-04-12 CA CA002683444A patent/CA2683444A1/en not_active Abandoned
- 2008-04-12 EP EP08742866A patent/EP2139476A1/en not_active Withdrawn
- 2008-04-12 JP JP2010503086A patent/JP2010523682A/ja active Pending
- 2008-04-12 WO PCT/US2008/004809 patent/WO2008127714A1/en not_active Ceased
- 2008-04-12 US US12/595,134 patent/US20100158858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2497526C2 (ru) | Производные бензилбензола и способы их применения | |
| WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| RU2012123372A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| JP2016538313A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| RU2012117786A (ru) | Новое производное фенола | |
| UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
| JP2011502958A5 (enExample) | ||
| HRP20120696T1 (hr) | Spiro-prstenasti spoj i njegova medicinska upotreba | |
| UA88104C2 (ru) | Производные пиридазинона как агонисты рецептора тиреоидного гормона | |
| JP2007519649A5 (enExample) | ||
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| JP2015187156A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| JP2017504611A5 (enExample) | ||
| JP2012530765A5 (enExample) | ||
| BRPI0511327B8 (pt) | combinações de glicopirrolato e agonistas do adrenorreceptor beta2 | |
| RU2008142600A (ru) | Органическое соединение | |
| JO2784B1 (en) | 5,3,1 - Triazole substitute derivative | |
| JP2016500063A5 (enExample) | ||
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos |